SYS-CON MEDIA Authors: Stackify Blog, Zakia Bouachraoui, Elizabeth White, Pat Romanski, Liz McMillan

News Feed Item

Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research



TOKYO, Dec 6, 2018 - (JCN Newswire) - Eisai Co., Ltd. and University College London (UCL) announced today that they have commenced preparations for Phase I clinical studies on E2814, the first clinical candidate from their drug discovery collaboration, in Alzheimer's disease patients within fiscal 2018. E2814 is an anti-tau monoclonal antibody which is designed to slow the progression of Alzheimer's disease and other tauopathies(1).

In addition, the research collaboration, agreed in 2012 for an initial period of six years, has been extended for a further 5 years to 2023. It was established as part of Eisai's Open Innovation strategy to collaborate with leading researchers in order to translate new research findings into innovative treatments for patients with neurodegenerative diseases. E2814 is one outcome out of a portfolio of projects established during the first phase of the collaboration with UCL.
Alzheimer's disease is a chronic, progressive, neurodegenerative disease characterized by formation of protein deposits known as plaques (made of amyloid-beta protein) and neurofibrillary tangles (made of tau protein) in patient's brains. Tau "seeds"(2) are believed to spread between different areas of the brain as the disease advances. E2814 is uniquely designed to target the tau "seeds", preventing further build-up of neurofibrillary tangles and thus may slow the course of the disease.

There are an estimated approximately 50 million dementia patients worldwide. As the aging of the global population gathers pace, the number of dementia patients is expected to continue trending upward and increase to approximately 82 million patients in 2030 and approximately 152 million in 2050. Therefore, promoting initiatives to address dementia is a global issue and there are hopes that therapeutic agents that satisfy these unmet medical needs will be developed quickly.

Professor Alan Thompson, Dean of UCL Faculty of Brain Sciences, said "This unique research partnership brings together UCL's world-class academic research capabilities with the drug discovery expertise of industry. These results highlight the success of bringing together such complementary expertise."

"Significant unmet medical needs exist for neurodegenerative disorders such as Alzheimer's disease due to a lack of effective treatments that can prevent disease progression, and Eisai's mission is to contribute to overcoming these issues." said Teiji Kimura, Chief Discovery Officer of the Eisai Neurology Business Group. "By combining the knowledge of UCL, which conducts world-class research into neurodegenerative disorders and is the operational hub of the UK Dementia Research Institute, together with the knowledge of Eisai, who possesses a rich pipeline for dementia treatments, we are doing our utmost to link the results of joint research starting with E2814 to new medicines in order to contribute to patients who are awaiting curative therapies as soon as possible."

(1) A general term for a group of neurodegenerative diseases, such as Alzheimer's disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Pick's disease, that show tau protein accumulation in the brain as histopathology
(2) Specially shaped tau aggregates that have the ability to transfer between cells and spread

About E2814

An anti-tau monoclonal antibody, E2814 is being developed as a disease modifying agent for Alzheimer's disease and other tauopathies, Phase I clinical studies are expected to commence within fiscal 2018. The drug candidate was discovered as part of the research collaboration between Eisai and UCL and is designed to prevent the spreading of tau protein "seeds" within the brains of affected individuals.

About University College London

UCL was founded in 1826. We were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has over 38,000 students from 150 countries and over 12,000 staff. Our annual income is more than EUR 1 billion.

www.ucl.ac.uk | Follow us on Twitter @uclnews | Watch our YouTube channel YouTube.com/UCLTV

About the UK Dementia Research Institute (DRI)

Funded by the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK, the UK DRI draws world-leaders in dementia research into a single national institute. UCL is home to the operational headquarters of the UK DRI and forms the hub for research activities across the six national research centres, which are at UCL, the University of Cambridge, Cardiff University, the University of Edinburgh, Imperial College London and King's College London. By convening world-class dementia researchers to bring about ground-breaking approaches to dementia defined by close collaboration and access to exceptional research resources, the UK DRI aims to find better ways to care for patients.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Source: Eisai

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120




Copyright 2018 JCN Newswire . All rights reserved.

More Stories By ACN Newswire

Copyright 2008 ACN Newswire. All rights reserved. Republication or redistribution of ACN Newswire content is expressly prohibited without the prior written consent of ACN Newswire. ACN Newswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Serverless applications increase developer productivity and time to market, by freeing engineers from spending time on infrastructure provisioning, configuration and management. Serverless also simplifies Operations and reduces cost - as the Kubernetes container infrastructure required to run these applications is automatically spun up and scaled precisely with the workload, to optimally handle all runtime requests. Recent advances in open source technology now allow organizations to run Serv...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It's clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Th...
The benefits of automated cloud deployments for speed, reliability and security are undeniable. The cornerstone of this approach, immutable deployment, promotes the idea of continuously rolling safe, stable images instead of trying to keep up with managing a fixed pool of virtual or physical machines. In this talk, we'll explore the immutable infrastructure pattern and how to use continuous deployment and continuous integration (CI/CD) process to build and manage server images for any platform....
AI and machine learning disruption for Enterprises started happening in the areas such as IT operations management (ITOPs) and Cloud management and SaaS apps. In 2019 CIOs will see disruptive solutions for Cloud & Devops, AI/ML driven IT Ops and Cloud Ops. Customers want AI-driven multi-cloud operations for monitoring, detection, prevention of disruptions. Disruptions cause revenue loss, unhappy users, impacts brand reputation etc.
Atmosera delivers modern cloud services that maximize the advantages of cloud-based infrastructures. Offering private, hybrid, and public cloud solutions, Atmosera works closely with customers to engineer, deploy, and operate cloud architectures with advanced services that deliver strategic business outcomes. Atmosera's expertise simplifies the process of cloud transformation and our 20+ years of experience managing complex IT environments provides our customers with the confidence and trust tha...
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. This...
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
Public clouds dominate IT conversations but the next phase of cloud evolutions are "multi" hybrid cloud environments. The winners in the cloud services industry will be those organizations that understand how to leverage these technologies as complete service solutions for specific customer verticals. In turn, both business and IT actors throughout the enterprise will need to increase their engagement with multi-cloud deployments today while planning a technology strategy that will constitute a ...
GCP Marketplace is based on a multi-cloud and hybrid-first philosophy, focused on giving Google Cloud partners and enterprise customers flexibility without lock-in. It also helps customers innovate by easily adopting new technologies from ISV partners, such as commercial Kubernetes applications, and allows companies to oversee the full lifecycle of a solution, from discovery through management.
Using serverless computing has a number of obvious benefits over traditional application infrastructure - you pay only for what you use, scale up or down immediately to match supply with demand, and avoid operating any server infrastructure at all. However, implementing maintainable and scalable applications using serverless computing services like AWS Lambda poses a number of challenges. The absence of long-lived, user-managed servers means that states cannot be maintained by the service. Lo...
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
Using serverless computing has a number of obvious benefits over traditional application infrastructure - you pay only for what you use, scale up or down immediately to match supply with demand, and avoid operating any server infrastructure at all. However, implementing maintainable and scalable applications using serverless computing services like AWS Lambda poses a number of challenges. The absence of long-lived, user-managed servers means that states cannot be maintained by the service. Lo...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...